RELAPSED / REFRACTORY AML
Clinical trials for RELAPSED / REFRACTORY AML explained in plain language.
Never miss a new study
Get alerted when new RELAPSED / REFRACTORY AML trials appear
Sign up with your email to follow new studies for RELAPSED / REFRACTORY AML, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for tough leukemia: drug combo targets resistant cancer
Disease control Not yet recruitingThis study tests a drug called olutasidenib in 25 adults with a specific genetic form of acute myeloid leukemia (IDH1-mutated) that has returned or not responded to treatment, including the drug venetoclax. Participants take olutasidenib pills twice daily for 28-day cycles. If th…
Matched conditions: RELAPSED / REFRACTORY AML
Phase: PHASE2 • Sponsor: Timothy Pardee • Aim: Disease control
Last updated May 17, 2026 03:01 UTC
-
Donor immune cells take on stubborn leukemia in new trial
Disease control Not yet recruitingThis study tests a treatment for acute myeloid leukemia (AML) that has returned or not responded to standard therapy. It uses specially engineered immune cells (CD33 CAR-NK cells) from a healthy donor to target and kill cancer cells. The trial has two phases: first to find the sa…
Matched conditions: RELAPSED / REFRACTORY AML
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated May 06, 2026 16:02 UTC